Urodynamix Data to be Presented at Leading Trauma Conference

VANCOUVER, British Columbia, May 8, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) today announced that an abstract describing the use of its near-infrared spectroscopy (“NIRS”) prototype for monitoring intra-abdominal pressure (“IAP”) in critical care ICU patients has been accepted for presentation at the Trauma Association of Canada’s Annual Scientific Meeting in Ottawa, Ontario, May 10-12, 2007.

The abstract entitled “NIRS as a Physiologic Monitor for Intra-Abdominal Hypertension (IAH)” will be presented by Drs. Sandy Widder, MD, FRCSC and Andrew Kirkpatrick, MD, FRCSC, FACS, Associate Professor of Surgery and Critical Care Medicine at the University of Calgary and Foothills Medical Centre in Calgary, Alberta. Clinical trials of the Company’s prototype NIRS device are currently underway in the critical care ICU at Foothills Medical Centre.

“Intra-abdominal pressure is known to be an important parameter in critically ill patients,” stated Dr. Kirkpatrick, Principal Investigator, Medical Director of Trauma for the Calgary Health Region and President-elect of the Trauma Association of Canada. “Our preliminary studies showed that monitoring the abdominal wall using NIRS is a safe method of measuring changes associated with IAP, and we recently expanded the trial protocol to study a greater number of ICU patients using more frequent IAP readings over longer periods of critical illness.”

Urodynamix is developing a NIRS-based monitor for continuous, non-invasive evaluation of critical care patients at risk of developing abdominal compartment syndrome (“ACS”), a life-threatening condition that occurs in patients with traumatic, hemorrhagic, surgical or vascular injuries. ACS requires prompt recognition and intervention, and the Company believes that a device based on its prototype can be used to track IAP like a vital sign, replacing more invasive and unreliable techniques currently used to monitor these patients.

“Urodynamix’s technology holds great promise in a wide range of medical applications with the potential to provide significant clinical benefits to patients,” said Dr. Andrew Macnab, MD, FRCPC, FRCPCH, chair of the Company’s medical advisory board and Professor of Pediatrics at the University of British Columbia. “We look forward to collaborating with Urodynamix in their effort to develop and expand their capabilities in these exciting new markets.”

About Abdominal Compartment Syndrome

Abdominal compartment syndrome (“ACS”) is multiple organ dysfunction caused by sustained elevated intra-abdominal pressure (“IAP”), the pressure concealed within the abdominal cavity. Physical examination is not an accurate indicator of elevated IAP, which presents in up to 50% of critically ill patients. Increases in IAP can rapidly advance to ACS, which is fatal if untreated.

Approximately 5 million North American patients are treated in ICUs every year, and current IAP monitoring techniques rely on manual, intermittent, and highly invasive catheter- or needle-based procedures. Continuous IAP monitoring may allow clinicians to avoid the onset of ACS by intervening before organ dysfunction develops, resulting in significant cost savings and improved patient outcomes. The global market for an automated, non-invasive IAP monitoring device is estimated to be in excess of $2 billion.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urinary incontinence in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company’s disruptive technology has the potential to beneficially affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Craig Pamplin, PhD, CFA
Director, Corporate Development and Communications
Urodynamix Technologies Ltd.
Tel: (604) 638-0247
Email: cpamplin@urodynamix.com
www.urodynamix.com